AI-Powered SCLC Research

SCLC is the most aggressive lung cancer subtype with rapid doubling time. AI agents research DLL3-targeted therapies, immunotherapy combinations, and lurbinectedin alternatives.

Standard of Care

Platinum/etoposide + atezolizumab or durvalumab, lurbinectedin (2nd line), topotecan.

Prevalence

~35,000 new SCLC diagnoses per year in the US (~15% of lung cancers).

Five-Year Survival

Extensive stage: ~3%. With chemo-immunotherapy: median ~13 months.

Key Mutations

• TP53 (>90%)
• RB1 (>90%)
• NOTCH pathway
• MYC amplification
• DLL3 expression

Key Pathways

• notch-signaling
• pd-1-pd-l1
• dna-damage-repair

Clinical Trial Focus

Tarlatamab (DLL3 BiTE), iadademstat (LSD1 inhibitor), PARP + temozolomide, DLL3-ADCs.